Advertisement

Archives of Pharmacal Research

, Volume 25, Issue 6, pp 879–884 | Cite as

Lb30057 inhibits platelet aggregation and vascular relaxation induced by thrombin

  • Byoung -In Jung
  • Kyu -Tae Kang
  • Ok -Nam Bae
  • Moo -Yeol Lee
  • Seung -Min Chung
  • Sang -Koo Lee
  • In -Chul Kim
  • Jin -Ho Chung
Research Articles Article
  • 43 Downloads

Abstract

Previous study showed that an amidrazonophenylalanine derivative, LB30057, which has high water solubility, inhibited the catalytic activity of thrombin potently by interaction with the active site of thrombin. In the current investigation, we examined whether LB30057 inhibited platelet aggregation and vascular relaxation induced by thrombin. Treatment with LB30057 to platelet-rich plasma (PRP) isolated from human blood resulted in a concentration-dependent inhibition of thrombin-induced aggregation. Values for IC50 and IC100 were 54±4 nM and 96±3 nM, respectively. This inhibition was agonist (thrombin) specific, since IC50 values for collagen and ADP were much greater than those for thrombin. In addition, concentration-dependent inhibitory effects were observed on the serotonin secretion induced by thrombin in PRP. Consistent with these findings, thrombin-induced increase in cytosolic calcium levels was inhibited in a concentration-dependent manner. When LB30057 was treated with aortic rings isolated from rats, LB30057 resulted in a concentration-dependent inhibition of thrombin-induced vascular relaxation. All these results suggest that LB30057 is a potent inhibitor of platelet aggregation and blood vessel relaxation induced by thrombin.

Key words

LB30057 Platelet-rich plasma Thrombin inhibitor 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Authi, K. S., Localization of the [32P]IP3 binding site on human platelet intracellular membranes isolated by high-voltage free-flow electrophoresis.FEBS Lett., 298, 173–176 (1992).PubMedCrossRefGoogle Scholar
  2. Becker, R. C., Thrombin antagonists and antiplatelet agents.Am. J. Cardiol., 69, 39A-51A (1992).PubMedCrossRefGoogle Scholar
  3. Eidt, J. F., Allison, P., Noble, S., Ashton, J., Golino, P., McNatt, J., Buja, L. M. and Willerson, J. T., Thrombin is an important mediator of platelet aggregation in stenosed canine coronary arteries with endothelial injury.J. Clin. Invest., 84, 18–27 (1989).PubMedCrossRefGoogle Scholar
  4. Gustafsson, D., Antonsson, T., Bylund, R., Eriksson, U., Gyzander, E., Nilsson, I., Elg, M., Mattsson, C., Deinum, J., Pehrsson, S., Karlsson, O., Nilsson, A. and Sorensen, H., Effects of melagatran, a new low-molecular-weight thrombin inhibitor, on thrombin and fibrinolytic enzymes.Thromb. Haemost., 79, 110–118 (1998).PubMedGoogle Scholar
  5. Hirsh, J., Heparin.N. Engl. J. Med., 324, 1565–1574 (1991).PubMedGoogle Scholar
  6. Hughes, P. E. and Pfaff, M., Integrin affinity modulation.Trends Cell Biol., 8, 359–364 (1998).PubMedCrossRefGoogle Scholar
  7. Hursting, M. J., Alford, K. L., Becker, J. C., Brooks, R. L., Joffrion, J. L., Knappenberger, G. D., Kogan, P. W., Kogan, T P., McKinney, A. A. and Schwarz, R. P., Jr., Novastan (brand of argatroban): a small-molecule, direct thrombin inhibitor.Semin. Thromb. Hemost., 23, 503–516 (1997).PubMedCrossRefGoogle Scholar
  8. Kelton, J. G., Sheridan, D., Santos, A., Smith, J., Steeves, K., Smith, C., Brown, C. and Murphy, W. G., Heparin-induced thrombocytopenia: laboratory studies.Blood, 72, 925–930 (1988).PubMedGoogle Scholar
  9. Lee, S. K., Lee, J. Y., Lee, M. Y., Chung, S. M. and Chung, J. H., Advantages of calcium green-1 over other fluorescent dyes in measuring cytosolic calcium in platelets.Anal. Biochem, 273, 186–191 (1999).PubMedCrossRefGoogle Scholar
  10. Matsuo, T., Koide, M. and Kario, K., Development of argatroban, a direct thrombin inhibitor, and its clinical application.Semin. Thromb. Hemost., 23, 517–522 (1997).PubMedGoogle Scholar
  11. Oh, Y. S., Yun, M., Hwang, S. Y., Hong, S., Shin, Y., Lee, K., Yoon, K. H., Yoo, Y. J., Kim, D. S., Lee, S. H., Lee, Y. H., Park, H. D., Lee, C. H., Lee, S. K. and Kim, S., Discovery of LB30057, a benzamidrazone-based selective oral thrombin inhibitor.Bioorg. Med. Chem. Lett., 8, 631–634 (1998).PubMedCrossRefGoogle Scholar
  12. Ripka, W. C., New thrombin inhibitors in cardiovascular disease.Curr. Opin. Chem. Biol., 1, 242–253 (1997).PubMedCrossRefGoogle Scholar
  13. Ross, R., The pathogenesis of atherosclerosis: a perspective for the 1990s.Nature, 362, 801–809 (1993).PubMedCrossRefGoogle Scholar
  14. Turpie, A. G., Weitz, J. I. and Hirsh, J., Advances in antithrombotic therapy: novel agents.Thromb. Haemost., 74, 565–571 (1995).PubMedGoogle Scholar
  15. Van Nueten, J. M., Leysen, J. E., de Clerck, F. and Vanhoutte, P. M., Serotonergic receptor subtypes and vascular reactivity.J. Cardiovasc. Pharmacol., 6 Suppl 4, S564-S574 (1984).PubMedGoogle Scholar
  16. Vanhoutte, P. M., 5-hydroxytryptamine and vascular disease.Fed. Proc., 42, 233–237 (1983).PubMedGoogle Scholar
  17. Vanhoutte, P. M. and Houston, D. S., Platelets, endothelium, and vasospasm.Circulation, 72, 728–734 (1985).PubMedGoogle Scholar
  18. Weitz, J. I., Biological rationale for the therapeutic role of specific antithrombins.Coron. Artery Dis,. 7, 409–419 (1996).CrossRefGoogle Scholar
  19. Zimmerman, G. A., Elstad, M. R., Lorant, D. E., Mclntyre, T. M., Prescott, S. M., Topham, M. K., Weyrich, A. S. and Whatley, R. E., Platelet-activating factor (PAF): signalling and adhesion in cell-cell interactions.Adv. Exp. Med. Biol., 416, 297–304 (1996).PubMedGoogle Scholar

Copyright information

© The Pharmaceutical Society of Korea 2002

Authors and Affiliations

  • Byoung -In Jung
    • 1
  • Kyu -Tae Kang
    • 1
  • Ok -Nam Bae
    • 1
  • Moo -Yeol Lee
    • 1
  • Seung -Min Chung
    • 1
  • Sang -Koo Lee
    • 2
  • In -Chul Kim
    • 2
  • Jin -Ho Chung
    • 1
  1. 1.Research Institute of Pharmaceutical Sciences, College of PharmacySeoul National UniversitySeoulKorea
  2. 2.Biotech Research Institute, LG ChemicalTaejonKorea

Personalised recommendations